CFB
FLGT icon

Cullen/Frost Bankers’s Fulgent Genetics FLGT Stock Holding History

Cullen/Frost Bankers’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-58
Closed -$1.68K – 1029
2023
Q4 		$1.68K Buy
+58
New +$1.55K ﹤0.01% 962

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cullen/Frost Bankers's FLGT Position: Q1 2024 in Review

Cullen/Frost Bankers sold out of Fulgent Genetics (FLGT) in Q1 2024, closing a stake of 58 shares — an estimated $1.68K sold.

Cullen/Frost Bankers first reported a position in FLGT in Q4 2023 and held it in 1 quarter. The position peaked at $1.68K in Q4 2023. 180 funds tracked by Wall St. Rank hold FLGT as of Q1 2024.

  • Cullen/Frost Bankers reported no remaining Fulgent Genetics position as of Q1 2024 after selling out during the quarter.
  • Cullen/Frost Bankers sold 58 Fulgent Genetics shares in Q1 2024, an estimated $1.68K.
  • Cullen/Frost Bankers first reported a position in Fulgent Genetics in Q4 2023 and held it in 1 quarter.
  • Cullen/Frost Bankers's Fulgent Genetics position peaked at $1.68K in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2024.

Based on Cullen/Frost Bankers's 13F filing for Q1 2024, filed 10 May 2024.